Specifically, Kumaran and colleagues reported that a loss in MLIP CNVs was associated with significant reduction in the breast cancer risk and recurrence-free survival, with a reported hazard ratio of 0.62 [0.4–0.94] [39]. This evidence concerns the gene MLIP and breast cancer.